G-CSF在ART治疗中不增加不良围产结局风险
该回顾性研究纳入接受卵子捐赠的反复流产且KIR-HLA-C错配合并ART治疗患者,比较妊娠期使用G-CSF(33例活产儿)与未使用(3798例儿童)的围产结局,发现两组在早产率、低出生体重等指标上无显著差异,结论认为G-CSF不增加围产并发症风险。
要点
- G-CSF组与对照组的早产率(<36周:10.0% vs 9.5%,P=0.783)无显著差异。
- 低出生体重(<2500g:19.6% vs 11.8%,P=0.570)发生率两组无显著差异。
- 极低出生体重(<1500g:2.5% vs 0.0%,P=0.454)两组无显著差异。
核心结论
- 在卵子捐赠ART治疗的反复流产且KIR-HLA-C错配患者中,胚胎移植时及妊娠早期使用G-CSF不增加围产并发症风险。
研究设计与样本
- 回顾性研究,纳入接受卵子捐赠的女性,G-CSF组33例活产儿,对照组3798例儿童,比较围产结局。
主要发现
- 母亲年龄:对照组40.9±0.1岁 vs G-CSF组38.9±1.8岁,P=0.055。
- 新生儿出生体重:对照组2952±200 g vs G-CSF组3145±270 g,P=0.184。
- 早产率(<36周):对照组10.0% vs G-CSF组9.5%,P=0.783;<32周:对照组2.2% vs G-CSF组0.0%,P=0.585。
- 低出生体重(<2500g):对照组19.6% vs G-CSF组11.8%,P=0.570;极低出生体重(<1500g):对照组2.5% vs G-CSF组0.0%,P=0.454。
临床怎么用
- 对于接受卵子捐赠ART治疗的反复流产且KIR-HLA-C错配患者,妊娠早期使用G-CSF未显示增加不良围产结局的风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Granulocyte colony-stimulating factor (G-CSF) acts on reproductive function at different stages, but its effects on the early stages of embryo development are unknown. The aim of this study was to assess the effect of G-CSF administration during treatment with assisted reproductive technologies (ART) and early pregnancy on newborns. DESIGN: Retrospective study in women undergoing egg donation, with a study group including 33 live-born children from a pregnancy in which G-CSF was administered, and a control group of 3798 children in which this medication was not ordered during pregnancy. The analysis was of perinatal outcomes resulting from G-CSF treatment administered off-label compared with a control group. RESULTS: No significant differences were found in maternal age (40.9 ± 0.1 versus 38.9 ± 1.8, P = 0.055), body mass index (23.2 ± 0.2 versus 22.6 ± 1.5, P = 0.503), infant birthweight (2952 ± 200 versus 3145 ± 270 g, P = 0.184), gestational age (38 ± 1 versus 37 ± 1 weeks, P = 0.926) or length (50.2 ± 1.5 versus 48.7 ± 2.7 cm, P = 0.678) (between the control group and women treated with G-CSF, respectively). The prematurity rates of births before week 36 (10.0% versus 9.5%, P = 0.783) or week 32 (2.2% versus 0.0%, P = 0.585) were similar in the control and study groups, respectively. The incidence of low birthweight (<2500 g; 19.6% versus 11.8%, P = 0.570) or very low birthweight (1500 g; 2.5% versus 0.0%, P = 0.454) was not significantly different between non-treated and G-CSF-treated women, respectively. CONCLUSIONS: Administration of G-CSF at embryo transfer and during early pregnancy in recurrent miscarriage patients with KIR-HLA-C mismatch undergoing egg donation ART treatment does not convey a higher risk of perinatal complications.
引用
- Cruz M, Alecsandru D, García-Velasco JA, et al. Use of granulocyte colony-stimulating factor in ART treatment does not increase the risk of adverse perinatal outcomes. Reprod Biomed Online. 2019. PMID: 31680063. doi:10.1016/j.rbmo.2019.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。